| Objective: To observe the clinical study of He Ne laser combine with compound betamethasone local injection in the treatment of alopecia areata (AA). Method: Used random number table, 100 AA patients who were admitted to our hospital from March 2020 to July 2024 were divided into control group (treated with compound betamethasone local injection, n=50) and study group (treated with He Ne laser combine with compound betamethasone local injection, n=50). The clinical efficacy, conventional scale scores [Skin Disease Quality of Life Index (DLQI), Patchy AA and severity of alopecia tool (SALT)], serum inflammatory factors [leukotriene C4, C-reactive protein (CRP), interleukin-10 (IL-10), soluble interleukin-2 receptor (sIL-2R)], immune function, and adverse reactions between two groups were compared. Result: The total clinical effective rate, IL-10, CD3+, CD4+, CD4+/CD8+ in the study group were higher than those in the control group after treatment, while the DLQI score, SALT score, leukotriene C4, CRP, SIL-2R, and CD8+ were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: He Ne laser combine with compound betamethasone local injection in the treatment of AA patients, can improve clinical efficacy, and symptoms, which may be related to the regulation of inflammatory factors and immune function, which is safe and reliable. |
